Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) ended Friday session in red amid volatile trading. The shares closed down -0.06 points or -1.43% at $4.14 with 1.60 million shares getting traded. Post opening the session at $4.21, the shares hit an intraday low of $4.09 and an intraday high of $4.25 and the price vacillated in this range throughout the day. The company has a market cap of $410.31 million and the numbers of outstanding shares have been calculated to be 100.55 million shares.
Celldex Therapeutics, Inc. (CLDX) announced that it has promoted Elizabeth Crowley to the newly created position of Senior Vice President, Chief Product Development Officer. Ms. Crowley was previously Senior Vice President of Product Development of Celldex and brings almost 25 years of industry experience where she was responsible for leading the execution of multiple successful drug development programs.
“Celldex was founded on the belief that combination regimens designed to unlock the power of the immune system would deliver the greatest benefit to the largest population of patients,” said Anthony Marucci, Co-founder, President and Chief Executive Officer of Celldex Therapeutics. “This newly created position is a direct response to the future of portfolio planning and drug development in the immuno-oncology field where we believe multi-drug combination regimens will become the norm and the development programs to explore these opportunities will become increasingly complex. Beth’s deep, oncology-focused experience in strategic planning, portfolio management and implementation have played a critical role in building the depth and breadth of our pipeline to date and an exceptional development operations team here at Celldex. We look forward to her continued expertise in this expanded leadership role.”
Shares of HCA Holdings Inc (NYSE:HCA) ended Friday session in red amid volatile trading. The shares closed down -0.36 points or -0.48% at $74.23 with 2.19 million shares getting traded. Post opening the session at $74.68, the shares hit an intraday low of $73.86 and an intraday high of $75.38 and the price vacillated in this range throughout the day. The company has a market cap of $27.97 billion and the numbers of outstanding shares have been calculated to be 378.65 million shares.
HCA Holdings Inc (HCA) announced the signing of an agreement to purchase Mobile Heartbeat, a leading developer of applications for smartphones to improve clinical workflow and team communications. Mobile Heartbeat technology solutions consolidate clinical communications, including alarms and notifications, patient information and lab data, secure texting, voice and photography.
HCA recently completed a successful pilot of Mobile Heartbeat’s CURE™ (Clinical Urgent Response) technology for its iMobile Project, an initiative to implement smartphone-based critical care team communications. HCA is launching Mobile Heartbeat’s CURE technology in 21 hospitals across the country with plans to implement the technology enterprise-wide.
“Mobile Heartbeat is an innovator that is keenly focused on meeting the mobile technology needs of clinicians,” said Dr. Jonathan Perlin, HCA’s chief medical officer and president of the Clinical Services Group. “This acquisition will enhance our ability to work closely with Mobile Heartbeat as we continue to create and refine technology solutions to improve clinical workflows and provide secure communications that foster better patient care.”